Tirzepatide, which is currently licensed for treatment of diabetes, could yield even better results than the latest class of jabs on the NHS
A new weight loss jab is twice as effective as its rivals in helping some dieters shed the pounds, new research suggests.
Scientists found that the treatment tirzepatide – currently licensed for treatment of diabetes – could yield even better results than the latest class of injections being offered on the NHS.
A study of 18,000 people found those given the medication lost almost a stone more than those given semaglutide, also known as Wegovy, when the treatment was administered for at least three months.
Ministers are keen to see widespread rollout of such drugs, in an effort to combat Britain’s obesity epidemic. Two in three UK adults are overweight or obese, costing the NHS £6.5 billion per year.